Use of etp46464 in the manufacture of a medicament for the treatment of colorectal cancer
ETP46464, by inhibiting ATR kinase activity, exhibits a significant selective killing effect on colorectal cancer cells as a single drug, solving the problems of drug resistance and disease progression of existing therapeutic drugs, and achieving highly efficient inhibition of colorectal cancer cells and control of tumor growth.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- KUNMING MEDICAL UNIVERSITY
- Filing Date
- 2026-06-10
- Publication Date
- 2026-07-17
AI Technical Summary
Existing drugs for treating colorectal cancer have issues with drug resistance and disease progression. Whether ETP46464 as a single drug can effectively inhibit the proliferation and migration of colorectal cancer cells remains inconclusive.
ETP46464, as a single drug, exhibited a significant selective killing effect on colorectal cancer cells. It inhibited the proliferation and migration of colorectal cancer cells by inhibiting ATR kinase activity, interfering with tumor cell cycle checkpoints, and suppressing tumor growth in mice.
ETP46464 significantly inhibits the proliferation and migration of colorectal cancer cells and effectively suppresses tumor growth in a mouse model, providing a new, highly effective, and low-toxicity treatment option for colorectal cancer.
Smart Images
Figure CN122398810A_ABST